Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned an average recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $7.83.

A number of research firms recently weighed in on AQST. Leerink Partnrs upgraded Aquestive Therapeutics to a “strong-buy” rating in a report on Friday, May 10th. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, June 5th. Raymond James started coverage on Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $7.00 target price on the stock. SVB Leerink started coverage on Aquestive Therapeutics in a research note on Friday, May 10th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics during the 1st quarter worth $54,000. Lazard Asset Management LLC lifted its stake in shares of Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares during the period. Jump Financial LLC purchased a new position in shares of Aquestive Therapeutics during the 4th quarter worth $60,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after purchasing an additional 30,898 shares during the period. Finally, PFG Investments LLC purchased a new position in shares of Aquestive Therapeutics during the 1st quarter worth $204,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

AQST opened at $2.60 on Friday. The stock has a market cap of $236.70 million, a P/E ratio of -6.19 and a beta of 2.81. The stock’s 50 day simple moving average is $3.09 and its 200 day simple moving average is $3.18. Aquestive Therapeutics has a 1-year low of $1.25 and a 1-year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The company had revenue of $12.05 million during the quarter, compared to analyst estimates of $12.22 million. During the same quarter in the prior year, the company posted $0.11 EPS. Research analysts expect that Aquestive Therapeutics will post -0.49 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.